Midwest Kidney Network

midwestkidneynetwork.org

Midwest Kidney Network is a private, nonprofit organization founded to improve care for patients with end stage renal disease ESRD. Established in 1978, the Renal Network of the Upper Midwest, Inc. (ESRD Network 11) is one of 18 regional ESRD Networks in the United States. We serve Michigan, Minnesota, North Dakota, South Dakota, and Wisconsin.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIOTECHS WORKING CLOSELY & FEVERISHLY WITH CDC FOR COVID-19 VACCINE DEVELOPMENT

PR Newswire | April 07, 2020

news image

Many companies searching for an effective therapy or vaccine for the present world health crisis are focusing on creating a vaccine from the immune system. Key to the race to develop a vaccine for the new coronavirus is a technology that uses the virus' genetic code to essentially persuade your body to make its own vaccine. This technique is faster than egg-based manufacturing, which produces the majority of annual flu vaccines… And it's enabling a possible vaccine for the new cor...

Read More

Industrial Impact, Medical

NIMBLE THERAPEUTICS DELIVERS LEAD COMPOUNDS FOR TWO PROGRAMS UNDER COLLABORATION WITH LARGE PHARMA PARTNER, TRIGGERING MILESTONE PAYMENTS

Nimble Therapeutics | December 14, 2022

news image

Nimble Therapeutics Inc., a leading peptide therapeutics company, announced they have achieved discovery milestones for two programs partnered with a large pharma company. For each program, Nimble has delivered lead compounds ready for further pre-clinical testing and subsequent IND studies. As with all its partnered research programs, Nimble remains eligible for additional future pre-clinical, clinical, and commercial milestones, and royalties attached to each program as development progresses....

Read More

Cell and Gene Therapy, Industrial Impact

CBM ANNOUNCES PARTNERSHIP WITH VIRION THERAPEUTICS

Center for Breakthrough Medicines | February 27, 2023

news image

Center for Breakthrough Medicines (CBM), a leading contract development and manufacturing organization dedicated to addressing the challenges of commercializing cell and gene therapies, and Virion Therapeutics, a clinical-stage biotech firm focused on developing accessible and adaptable CD8+ T cell-based technologies for cancer and infectious diseases, have recently announced a strategic collaboration agreement. CBM will partner and manufacture with Virion Therapeutics on their ...

Read More

METASTASIS BLOCKING ANTIBODY SHOWS PRECLINICAL PROMISE

Genetic Engineering and Biotechnology News | April 24, 2020

news image

Investigators at the German Cancer Research Center in Heidelberg (DKFZ) and the Mannheim Medical Faculty of the University of Heidelberg have released data on an antibody they created that blocks a receptor that stimulates the formation of new blood vessels in tumors and metastasis. Findings from the new stud—published recently in EMBO Molecular Medicine through an article entitled “Preclinical validation of a novel metastasis‐inhibiting Tie1 function‐blocking antibody”—s...

Read More
news image

BIOTECHS WORKING CLOSELY & FEVERISHLY WITH CDC FOR COVID-19 VACCINE DEVELOPMENT

PR Newswire | April 07, 2020

Many companies searching for an effective therapy or vaccine for the present world health crisis are focusing on creating a vaccine from the immune system. Key to the race to develop a vaccine for the new coronavirus is a technology that uses the virus' genetic code to essentially persuade your body to make its own vaccine. This technique is faster than egg-based manufacturing, which produces the majority of annual flu vaccines… And it's enabling a possible vaccine for the new cor...

Read More
news image

Industrial Impact, Medical

NIMBLE THERAPEUTICS DELIVERS LEAD COMPOUNDS FOR TWO PROGRAMS UNDER COLLABORATION WITH LARGE PHARMA PARTNER, TRIGGERING MILESTONE PAYMENTS

Nimble Therapeutics | December 14, 2022

Nimble Therapeutics Inc., a leading peptide therapeutics company, announced they have achieved discovery milestones for two programs partnered with a large pharma company. For each program, Nimble has delivered lead compounds ready for further pre-clinical testing and subsequent IND studies. As with all its partnered research programs, Nimble remains eligible for additional future pre-clinical, clinical, and commercial milestones, and royalties attached to each program as development progresses....

Read More
news image

Cell and Gene Therapy, Industrial Impact

CBM ANNOUNCES PARTNERSHIP WITH VIRION THERAPEUTICS

Center for Breakthrough Medicines | February 27, 2023

Center for Breakthrough Medicines (CBM), a leading contract development and manufacturing organization dedicated to addressing the challenges of commercializing cell and gene therapies, and Virion Therapeutics, a clinical-stage biotech firm focused on developing accessible and adaptable CD8+ T cell-based technologies for cancer and infectious diseases, have recently announced a strategic collaboration agreement. CBM will partner and manufacture with Virion Therapeutics on their ...

Read More
news image

METASTASIS BLOCKING ANTIBODY SHOWS PRECLINICAL PROMISE

Genetic Engineering and Biotechnology News | April 24, 2020

Investigators at the German Cancer Research Center in Heidelberg (DKFZ) and the Mannheim Medical Faculty of the University of Heidelberg have released data on an antibody they created that blocks a receptor that stimulates the formation of new blood vessels in tumors and metastasis. Findings from the new stud—published recently in EMBO Molecular Medicine through an article entitled “Preclinical validation of a novel metastasis‐inhibiting Tie1 function‐blocking antibody”—s...

Read More